103 related articles for article (PubMed ID: 38563164)
21. Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma.
Chiesa S; Mangraviti A; Martini M; Cenci T; Mazzarella C; Gaudino S; Bracci S; Martino A; Della Pepa GM; Offi M; Gessi M; Russo R; Martucci M; Beghella Bartoli F; Larocca LM; Lauretti L; Olivi A; Pallini R; Balducci M; D'Alessandris QG
Sci Rep; 2022 Sep; 12(1):16265. PubMed ID: 36171338
[TBL] [Abstract][Full Text] [Related]
22. Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity.
Treiber H; von der Brelie C; Malinova V; Mielke D; Rohde V; Chapuy CI
Neurosurg Rev; 2022 Oct; 45(5):3201-3208. PubMed ID: 35725846
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas.
Werner JM; Wolf L; Tscherpel C; Bauer EK; Wollring M; Ceccon G; Deckert M; Brunn A; Pappesch R; Goldbrunner R; Fink GR; Galldiks N
J Neurooncol; 2022 Sep; 159(2):309-317. PubMed ID: 35716310
[TBL] [Abstract][Full Text] [Related]
24. Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells.
Deshors P; Arnauduc F; Boëlle B; Cohen-Jonathan Moyal E; Courtade-Saïdi M; Evrard SM
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326702
[TBL] [Abstract][Full Text] [Related]
25. Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.
Chiang IT; Liu YC; Liu HS; Ali AAA; Chou SY; Hsu TI; Hsu FT
Neurotherapeutics; 2022 Mar; 19(2):616-634. PubMed ID: 35267171
[TBL] [Abstract][Full Text] [Related]
26. Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review.
Gatto L; Franceschi E; Tosoni A; Di Nunno V; Maggio I; Tonon C; Lodi R; Agati R; Bartolini S; Brandes AA
Clin Case Rep; 2021 Aug; 9(8):e04604. PubMed ID: 34457284
[TBL] [Abstract][Full Text] [Related]
27. Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).
Lombardi G; Del Bianco P; Brandes AA; Eoli M; Rudà R; Ibrahim T; Lolli I; Rizzato S; Daniele B; Pace A; Pasqualetti F; Caccesse M; Bergo E; Magni G; De Salvo GL; Zagonel V
Eur J Cancer; 2021 Sep; 155():179-190. PubMed ID: 34388515
[TBL] [Abstract][Full Text] [Related]
28. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
Louis DN; Perry A; Wesseling P; Brat DJ; Cree IA; Figarella-Branger D; Hawkins C; Ng HK; Pfister SM; Reifenberger G; Soffietti R; von Deimling A; Ellison DW
Neuro Oncol; 2021 Aug; 23(8):1231-1251. PubMed ID: 34185076
[TBL] [Abstract][Full Text] [Related]
29. A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib.
Santangelo A; Rossato M; Lombardi G; Benfatto S; Lavezzari D; De Salvo GL; Indraccolo S; Dechecchi MC; Prandini P; Gambari R; Scapoli C; Di Gennaro G; Caccese M; Eoli M; Rudà R; Brandes AA; Ibrahim T; Rizzato S; Lolli I; Lippi G; Delledonne M; Zagonel V; Cabrini G
Neuro Oncol; 2021 Feb; 23(2):264-276. PubMed ID: 32661549
[TBL] [Abstract][Full Text] [Related]
30. Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis.
Indraccolo S; De Salvo GL; Verza M; Caccese M; Esposito G; Piga I; Del Bianco P; Pizzi M; Gardiman MP; Eoli M; Rudà R; Brandes AA; Ibrahim T; Rizzato S; Lolli I; Zagonel V; Lombardi G
Clin Cancer Res; 2020 Sep; 26(17):4478-4484. PubMed ID: 32518098
[TBL] [Abstract][Full Text] [Related]
31. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.
Ostrom QT; Cioffi G; Gittleman H; Patil N; Waite K; Kruchko C; Barnholtz-Sloan JS
Neuro Oncol; 2019 Nov; 21(Suppl 5):v1-v100. PubMed ID: 31675094
[TBL] [Abstract][Full Text] [Related]
32. Ionizing radiation induces endothelial transdifferentiation of glioblastoma stem-like cells through the Tie2 signaling pathway.
Deshors P; Toulas C; Arnauduc F; Malric L; Siegfried A; Nicaise Y; Lemarié A; Larrieu D; Tosolini M; Cohen-Jonathan Moyal E; Courtade-Saidi M; Evrard SM
Cell Death Dis; 2019 Oct; 10(11):816. PubMed ID: 31659157
[TBL] [Abstract][Full Text] [Related]
33. Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma.
Jiang J; Zhang L; Chen H; Lei Y; Zhang T; Wang Y; Jin P; Lan J; Zhou L; Huang Z; Li B; Liu Y; Gao W; Xie K; Zhou L; Nice EC; Peng Y; Cao Y; Wei Y; Wang K; Huang C
Autophagy; 2020 Jan; 16(1):106-122. PubMed ID: 30909789
[TBL] [Abstract][Full Text] [Related]
34. Drug development for glioma: are we repeating the same mistakes?
Stupp R
Lancet Oncol; 2019 Jan; 20(1):10-12. PubMed ID: 30522968
[No Abstract] [Full Text] [Related]
35. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lombardi G; De Salvo GL; Brandes AA; Eoli M; Rudà R; Faedi M; Lolli I; Pace A; Daniele B; Pasqualetti F; Rizzato S; Bellu L; Pambuku A; Farina M; Magni G; Indraccolo S; Gardiman MP; Soffietti R; Zagonel V
Lancet Oncol; 2019 Jan; 20(1):110-119. PubMed ID: 30522967
[TBL] [Abstract][Full Text] [Related]
36. Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1.
Falchetti ML; D'Alessandris QG; Pacioni S; Buccarelli M; Morgante L; Giannetti S; Lulli V; Martini M; Larocca LM; Vakana E; Stancato L; Ricci-Vitiani L; Pallini R
Int J Cancer; 2019 Mar; 144(6):1331-1344. PubMed ID: 30414187
[TBL] [Abstract][Full Text] [Related]
37. cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
Brat DJ; Aldape K; Colman H; Holland EC; Louis DN; Jenkins RB; Kleinschmidt-DeMasters BK; Perry A; Reifenberger G; Stupp R; von Deimling A; Weller M
Acta Neuropathol; 2018 Nov; 136(5):805-810. PubMed ID: 30259105
[No Abstract] [Full Text] [Related]
38. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.
Stichel D; Ebrahimi A; Reuss D; Schrimpf D; Ono T; Shirahata M; Reifenberger G; Weller M; Hänggi D; Wick W; Herold-Mende C; Westphal M; Brandner S; Pfister SM; Capper D; Sahm F; von Deimling A
Acta Neuropathol; 2018 Nov; 136(5):793-803. PubMed ID: 30187121
[TBL] [Abstract][Full Text] [Related]
39. Imaging Criteria in Neuro-oncology.
Nowosielski M; Wen PY
Semin Neurol; 2018 Feb; 38(1):24-31. PubMed ID: 29548049
[TBL] [Abstract][Full Text] [Related]
40. Lomustine and Bevacizumab in Progressive Glioblastoma.
Wick W; Gorlia T; Bendszus M; Taphoorn M; Sahm F; Harting I; Brandes AA; Taal W; Domont J; Idbaih A; Campone M; Clement PM; Stupp R; Fabbro M; Le Rhun E; Dubois F; Weller M; von Deimling A; Golfinopoulos V; Bromberg JC; Platten M; Klein M; van den Bent MJ
N Engl J Med; 2017 Nov; 377(20):1954-1963. PubMed ID: 29141164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
